FLUIDDA introduces proprietary Functional Respiratory Imaging (FRI) technology that provides a unique entry point into personalized medicine for respiratory diseases.

FRI benefits

FRI reduces the cost and time required for screening most promising new respiratory drugs by decreasing the number of patients needed for early stage clinical trials.  FRI identifies more quickly inefficient therapies, dramatically speeding time-to-market.

Read more


Functional respiratory imaging (FRI) is a proprietary quantitative imaging technology combining CT imaging with advanced engineering to construct 3D biomarkers.

Read more

FRI biomarkers

FRI technology provides patient-specific biomarkers: 3D visualization of patient’s airway and lung geometry that can monitor patient outcomes with high sensitivity never before possible.

Read more